A single dose of intravenous esomeprazole decreases gastric secretion in healthy volunteers

Aliment Pharmacol Ther. 2009 Nov 15;30(10):1022-9. doi: 10.1111/j.1365-2036.2009.04128.x. Epub 2009 Aug 21.


Background: Data suggest that esomeprazole decreases gastric secretion.

Aims: To assess the effect of a single i.v. esomeprazole dose on gastric secretion volume 3 h after drug administration, as a primary endpoint, and to evaluate, as secondary endpoints, the reduction 1 and 5 h after dosing; time when the gastric pH was <2.5 and esomeprazole's safety.

Methods: In all, 23 healthy Helicobacter pylori-negative volunteers (10 men, 13 women, mean age 28.2 +/- 6) participated in this single-centre, randomized, double-blind, placebo-controlled, 2-way, single-dose cross-over study. In different sessions, volunteers received i.v. either esomeprazole 40 mg or placebo. An inserted double-lumen nasogastric tube perfused and aspirated gastric liquid. Mechanical fractioned aspiration measured secretion volume; aliquot spectrophotometry assessed gastric secretion volume lost to the duodenum.

Results: Three hours post-i.v. esomeprazole, average gastric secretion decreased by 77.6% (vs. baseline) compared to placebo. Values 1 and 5 h after dosing were 73.5% and 74.5%. Five hours after esomeprazole, the gastric pH was <2.5 3.9% of the time and 73.3% after placebo (P < 0.002). Esomeprazole was well-tolerated. No serious adverse events occurred.

Conclusions: Intravenous esomeprazole decreases gastric secretions. The potential clinical impact in averting bronchoaspiration during anaesthesia induction and in intensive care patients should be investigated in further studies.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-Ulcer Agents / administration & dosage*
  • Anti-Ulcer Agents / pharmacology
  • Cross-Over Studies
  • Double-Blind Method
  • Esomeprazole / administration & dosage*
  • Esomeprazole / pharmacology
  • Female
  • Gastric Acid / metabolism*
  • Humans
  • Hydrogen-Ion Concentration / drug effects*
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Proton Pump Inhibitors
  • Treatment Outcome
  • Young Adult


  • Anti-Ulcer Agents
  • Proton Pump Inhibitors
  • Esomeprazole